WOCKHARDT LTD. - 532300 - Closure of Trading Window
This is to inform you that pursuant to Company''s Code of Conduct for regulating, monitoring and reporting trading by designated person, the trading window for dealing in the equity shares of the Company will be closed from 1st April, 2024 untill 48 hours of declaration of audited Financial Results of the Company for the financial year ended 31st March, 2024.
Wockhardt Shares Locked In 5% Upper Circuit After Raising Rs 480 Crore Via QIP
Post QIP, Wockhardt's paid-up equity share capital increased to Rs 76.71 crore, consisting of 15.34 equity shares with a face value of Rs 5 each. WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Allotment
The Capital raising Committee of the Company in its meeting held today i.e. 26th March, 2024 approved the issue and allotment of 92,85,163 Equity Shares to eligible QIBs. WOCKHARDT LTD. - 532300 - Board Meeting Outcome for Outcome Of The Meeting Of The Capital Raising Committee
The Capital Raising Committee of the Company has, at its meeting held today, i.e. Tuesday, 26th March, 2024, inter alia: approved the closure of Issue today, i.e. Tuesday, 26th March, 2024, and determined the allocation of 92,85,163 Equity Shares at an issue price of ?517/- per Equity Share (including a premium of ?512/- per Equity Share), which includes a discount of ?27.02/- per Equity Share equivalent to 4.97% to the floor price of ?544.02/- per Equity Share, determined as per the formula prescribed under Regulation 176(1) of the SEBI ICDR Regulations, for the Equity Shares to be allotted to the eligible QIBs in the Issue; approved and adopted the placement document dated 26th March, 2024 ('Placement Document') in connection with the Issue; and approved and finalized the confirmation of allocation note for sending to such QIBs to whom the allocation of Equity Shares pursuant to the issue is to be confirmed; Wockhardt Shares Gain As Rs 570-Crore QIP Opens
The issue opened on March 20 after market hours and will close on March 21, with an option to extend it further. WOCKHARDT LTD. - 532300 - Board Meeting Intimation for The Meeting Of The Capital Raising Committee Of The Company For Determination Of Issue Price.
WOCKHARDT LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/03/2024 ,inter alia, to consider and approve the issue price of Equity Shares to be issued pursuant to the Qualified institutions placement of equity shares by Wockhardt Limited. WOCKHARDT LTD. - 532300 - Board Meeting Outcome for Outcome Of The Meeting Of The Capital Raising Committee
We wish to inform you that the Capital Raising Committee of the Company, in its meeting held today i.e. 20th March, 2024, has inter alia considered and passed the following resolutions:(i) authorizing the opening of the Issue today, i.e. on 20th March, 2024; (ii)approving the floor price being ?544.02 per Equity Shares for the Issue as prescribed under the SEBI ICDR Regulations; and (iii)approval and adoption of the preliminary placement document dated 20th March, 2024, and the draft of application form, in connection with the Issue. We further wish to inform you that the 'Relevant Date' for the purpose of the Issue, in terms of the SEBI ICDR Regulations is 20th March, 2024 and accordingly the floor price in respect of the Issue, based on the pricing formula as prescribed under Regulation 176(1) of the SEBI ICDR Regulations, the Company may, at its discretion, offer a discount of not more than 5% (five percent) on the floor price so calculated for the Issue. WOCKHARDT LTD. - 532300 - Closure of Trading Window
This is to inform you that pursuant to Company''s Code of Conduct for Regulating, Monitoring and Reporting Trading by Designated Person, the trading window for dealing in Equity Shares of the Company will be closed form 19th March, 2024 untill further notice. WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
A leading European Journal reports a challenging clinical case of successful use of under-trial drug Zidebactum/Cefepime (WCK5222, ZaynichTM) to treat Skull bone infection & Pnuemonia caused by Extreme-drug Resistant Psuedomonas in renal transplant patient.
Wockhardt To Raise Rs 400 Crore Via QIPNDTV Profit Exclusive
The price for the QIP is likely to be based on the 10-day average price of Rs 561, people familiar with the matter said.